Haemophilus influenzae

Haemophilus influenzae is a small bacterium that lives quietly in the nose and throat of many perfectly healthy people — and yet, in its most dangerous form, it was once one of the leading causes of life-threatening childhood infections in the world. Its story is really two stories. The first is about a misleading name and a case of mistaken identity during a flu pandemic more than a century ago. The second is one of modern medicine's great triumphs: a vaccine that, in the countries that use it, has driven the deadliest form of this bacterium to the edge of extinction. This page explains what Haemophilus influenzae is, why it does not actually cause the flu, the difference between the type that once filled children's hospital wards and the everyday type that causes ear and sinus infections, and how vaccination changed everything.

Table of Contents

  1. What It Is
  2. The Misleading Name
  3. Type b (Hib) vs Non-typeable (NTHi)
  4. The Serious Invasive Diseases
  5. Everyday Infections from NTHi
  6. The Hib Vaccine Success Story
  7. How It Is Diagnosed
  8. Treatment
  9. Prevention
  10. Research Papers
  11. Connections
  12. Featured Videos

What It Is

Haemophilus influenzae is a Gram-negative coccobacillus — a fancy way of saying it is a very small, oval-to-rod-shaped bacterium whose cell wall stains pink (rather than purple) under the classic Gram stain that microbiologists use to sort bacteria into two big families. It is a human-only germ: it has no animal or environmental reservoir, and it spreads person-to-person through respiratory droplets from coughing, sneezing, and close contact.

Here is something surprising. Carrying this bacterium is normal. A large share of healthy people — and especially young children — harbor Haemophilus influenzae in the lining of their nose and throat without any symptoms at all. This harmless carriage is called colonization. Disease only happens when the bacterium slips past the body's defenses — either invading the bloodstream (in the dangerous encapsulated strains) or setting up a localized infection in the ear, sinus, or airway. Telling colonization apart from true infection is one of the practical challenges in diagnosis.

The bacterium is fastidious, meaning it is fussy about how it grows. In the laboratory it will not grow on ordinary blood agar. It needs two specific ingredients found inside blood: factor X (hemin, an iron-containing pigment) and factor V (a molecule called NAD). This blood-loving requirement is exactly where its genus name comes from — Haemophilus literally means "blood-lover" in Greek. To supply both factors, labs grow it on chocolate agar, which is not chocolate at all but blood agar that has been gently heated until the blood cells break open and release factors X and V, turning the plate a chocolate-brown color.

The Misleading Name

The species name — influenzae — is one of the most famous misnomers in all of microbiology. This bacterium does not cause influenza. The flu is caused by the influenza virus, an entirely different kind of germ that was not identified until 1933.

So why the name? During the great influenza pandemic of 1889–1892, the German bacteriologist Richard Pfeiffer examined the lungs and sputum of flu patients and repeatedly found this same little bacterium. In 1892 he concluded, reasonably given the science of the day, that he had discovered the cause of influenza. The organism was christened "Pfeiffer's bacillus" or Bacillus influenzae, and for decades many physicians believed it was the flu germ.

What was really happening is that Haemophilus influenzae is a common secondary invader. When a viral flu infection damages the airway lining, this bacterium — already sitting in the nose and throat — often takes advantage and causes a superimposed bacterial infection, such as pneumonia. Pfeiffer kept finding it in flu patients not because it caused the flu, but because it so frequently tagged along after the flu. By the time the true viral cause was proven in the 1930s, the name had stuck fast, and it remains with us today as a historical curiosity.

Type b (Hib) vs Non-typeable (NTHi)

The single most important thing to understand about this bacterium is that it comes in two broad varieties, and they behave completely differently. The dividing line is a capsule — a slippery, sugar-based outer coat that some strains wear and others do not.

Encapsulated strains wrap themselves in a polysaccharide (complex sugar) capsule. This capsule is a powerful weapon: it hides the bacterium from the immune system and makes it hard for white blood cells to grab and destroy. Encapsulated strains come in six varieties, labeled a through f, sorted by the chemical make-up of their capsule. This capsular typing scheme was worked out by the American scientist Margaret Pittman in 1931 (see Research Papers).

Of those six, one stands far above the rest for the harm it caused: type b, universally abbreviated Hib. Its capsule is built from a sugar-phosphate polymer called PRP (polyribosylribitol phosphate). This particular capsule is so effective at defeating the immune system that, before vaccination, Hib was responsible for the overwhelming majority of the severe, invasive, bloodstream-and-brain infections this species caused in young children. When people talk about Haemophilus influenzae as a childhood killer, they are almost always talking about Hib.

Non-typeable Haemophilus influenzae — abbreviated NTHi — is the strain that has no capsule. Because it cannot be assigned a capsular letter (a through f), it is called "non-typeable." Without the protective capsule it is far less able to invade the bloodstream, so it rarely causes the dramatic invasive disease that Hib did. Instead, NTHi is a specialist at mucosal infections — settling into the surfaces of the middle ear, the sinuses, and the airways. In the era after the Hib vaccine, NTHi has become the more common cause of Haemophilus disease overall, and it is increasingly recognized as an under-appreciated cause of illness in both children and adults (see Research Papers).

The Serious Invasive Diseases

Before a vaccine existed, Hib was a genuine scourge of early childhood. Invasive Hib disease struck hardest between 6 and 18 months of age, a window when a baby's own antibody defenses against the PRP capsule are still immature. The bacterium would cross from the throat into the bloodstream and seed serious infections throughout the body.

Meningitis was the most feared. Hib was, for most of the twentieth century, a leading cause of bacterial meningitis — infection of the membranes surrounding the brain and spinal cord — in young children. Even with prompt antibiotic treatment, Hib meningitis could be fatal, and among the children who survived, a substantial fraction were left with permanent consequences: deafness, seizures, developmental delay, and other forms of brain injury. A generation of pediatricians grew up dreading it.

Epiglottitis was, in many ways, even more frightening because it could kill within hours. The epiglottis is the small flap of tissue at the base of the tongue that folds down to protect the windpipe during swallowing. When Hib infects it, the epiglottis swells rapidly and can completely block the airway — a true breathing emergency. A classic case is a child who suddenly becomes very ill with a high fever, sits bolt upright leaning forward (the "tripod" position), drools because it hurts too much to swallow, has a muffled "hot-potato" voice, and makes a harsh noise breathing in. A critical safety point that every clinician learns: in suspected epiglottitis you must not poke around in the child's throat or force them to lie down, because doing so can trigger complete airway closure. Securing the airway comes first; everything else waits. (See our page on epiglottitis.)

Hib also caused a range of other invasive infections, including pneumonia (lung infection), septic arthritis (a bacterial joint infection, often in a hip or knee), cellulitis (a deep skin infection, characteristically on a child's cheek or around the eye), bacteremia and sepsis (bloodstream infection), osteomyelitis (bone infection), and occasionally pericarditis (infection of the sac around the heart). To grasp the sheer scale of the pre-vaccine burden: a landmark global analysis estimated that in the year 2000, Hib caused roughly 8 million serious illnesses and around 370,000 deaths in children under 5 worldwide — most of them from meningitis and pneumonia (see Research Papers).

Everyday Infections from NTHi

While Hib grabbed the headlines, the capsule-free NTHi strains were quietly causing an enormous number of far more common, far less dramatic infections — and they still do, because the Hib vaccine does nothing against them.

Otitis media (middle ear infection) is the classic NTHi illness. Haemophilus influenzae — almost entirely the non-typeable strains — is one of the top two or three bacterial causes of the ear infections that send so many toddlers to the doctor with ear pain, fever, and fussiness. NTHi is especially associated with recurrent and treatment-resistant ear infections (see Research Papers).

Sinusitis (infection of the sinus cavities) is another very common NTHi infection, often following a cold, causing facial pressure, congestion, and thick nasal discharge.

COPD exacerbations are where NTHi does its most serious damage in adults. In people with chronic obstructive pulmonary disease — the long-term lung condition caused mostly by smoking — NTHi is the most common bacterial cause of acute flare-ups, the episodes of worsened cough, breathlessness, and discolored phlegm that can land patients in the hospital. NTHi persistently colonizes the damaged airways of COPD patients, and acquiring a new strain is a recognized trigger for these exacerbations (see Research Papers).

NTHi also causes conjunctivitis ("pink eye," sometimes in outbreaks among children) and community-acquired pneumonia, particularly in older adults and those with underlying lung disease. In newborns, the elderly, pregnant women, and people with weakened immune systems, NTHi can occasionally break the usual rule and cause invasive bloodstream infection.

The Hib Vaccine Success Story

The Hib conjugate vaccine is one of the most successful public-health interventions of the modern era, and it deserves to be far better known. It is a genuine near-elimination story.

The challenge was scientific. The obvious idea — make a vaccine out of the PRP capsule sugar so the immune system learns to recognize it — was tried first, and it largely failed in the babies who needed it most. Plain polysaccharide sugars are what immunologists call "T-cell independent" antigens: the immature immune system of a child under about 18–24 months simply does not mount a strong, lasting antibody response to them. Since that is precisely the age of peak Hib danger, an early polysaccharide-only vaccine could not protect the most vulnerable group.

The breakthrough was the conjugate vaccine, developed in the 1980s. Scientists chemically linked ("conjugated") the PRP sugar to a carrier protein. That protein partner transforms the immune response: it recruits helper T-cells, which allows even young infants to build a strong, durable, memory-forming antibody response against the capsule. This same clever trick was later applied to pneumococcal and meningococcal vaccines.

Hib conjugate vaccines entered routine infant immunization schedules around 1990 in the United States and other wealthy countries, typically given as a series of shots in the first months of life (commonly around 2, 4, and 6 months, with a booster near 12–15 months) and often combined with other childhood vaccines in a single injection.

The results were swift and dramatic. In vaccinated populations, invasive Hib disease fell by about 99 percent — a near-complete disappearance of what had been a leading cause of childhood meningitis. A widely cited 1993 report documented the collapse of childhood Hib disease in the early vaccine years in the United States, and later global reviews confirmed the same pattern wherever the vaccine was introduced (see Research Papers). The vaccine works in a second way, too: it reduces the number of children who carry Hib in their throats, so even unvaccinated people are protected because the germ stops circulating — a benefit called herd immunity.

Two honest caveats keep the story accurate. First, the Hib vaccine is specific to type b. It does not protect against non-typeable strains or the other capsular types, which is exactly why NTHi ear infections, sinusitis, and COPD flare-ups continue undiminished. Second, the triumph is not yet universal. In regions where infants are under-vaccinated, Hib remains a real cause of childhood meningitis, pneumonia, and death — a reminder that this success depends entirely on sustained access to the vaccine (see Research Papers).

How It Is Diagnosed

Because Haemophilus influenzae lives harmlessly in many people's noses and throats, a positive swab from those areas does not by itself prove disease. Meaningful diagnosis focuses on finding the bacterium where it does not belong.

For serious invasive disease, the gold standard is a culture from a normally sterile site — blood, or the cerebrospinal fluid (CSF) drawn by a lumbar puncture (spinal tap) in suspected meningitis. Growing the fussy organism requires chocolate agar supplying factors X and V, as described above. In meningitis, examining the CSF is central: a Gram stain may reveal the tell-tale tiny Gram-negative coccobacilli, while a high white-cell count, low glucose, and high protein point to bacterial infection.

Modern laboratories increasingly use molecular tests (PCR) that detect the bacterium's DNA. These are especially valuable when a child has already received antibiotics before the sample was taken, which can render cultures falsely negative. Once the organism is identified, laboratories perform serotyping to determine whether it is type b or another type — information that matters for public-health tracking and for deciding whether close contacts need preventive antibiotics. For ear and sinus infections, treatment is usually started on clinical grounds without culturing, since sampling those sites directly is impractical.

Treatment

Invasive Haemophilus influenzae disease is a medical emergency treated with intravenous antibiotics, and getting the choice right has become more complicated because of resistance.

For decades, ampicillin (a penicillin-family drug) was the reliable treatment. That changed when strains began producing beta-lactamase — an enzyme that chops up and inactivates ampicillin and amoxicillin. A significant share of Haemophilus influenzae now carries this enzyme, so ampicillin can no longer be trusted for serious infections until the lab confirms the specific strain is susceptible. (A less common form of resistance, called BLNAR, comes from an altered drug target rather than an enzyme, and it defeats these drugs by a different route.)

Because of this, the modern first-line treatment for serious invasive disease — meningitis, epiglottitis, sepsis — is a third-generation cephalosporin, most often ceftriaxone or cefotaxime, given intravenously. These drugs resist beta-lactamase, reliably kill the bacterium, and cross into the cerebrospinal fluid well enough to treat meningitis. In epiglottitis, securing the airway takes absolute priority — often by placing a breathing tube in a controlled operating-room setting — before or alongside antibiotics, because an obstructed airway kills faster than the infection. In childhood Hib meningitis, adding the steroid dexamethasone alongside antibiotics has been used to reduce the risk of hearing loss.

Milder, non-invasive NTHi infections such as ear and sinus infections are typically treated with oral antibiotics. When a beta-lactamase–producing strain is likely, amoxicillin-clavulanate is a common choice — the clavulanate component blocks the beta-lactamase enzyme, rescuing the amoxicillin. Certain oral cephalosporins and other antibiotic classes are also used, guided by local resistance patterns and patient allergies.

Prevention

The cornerstone of prevention is unambiguous: routine infant Hib conjugate vaccination. Keeping children on schedule with their Hib shots is by far the most powerful tool for preventing the invasive, life-threatening forms of the disease, and it is why an entire generation of parents and doctors in vaccinating countries has never seen a case of Hib epiglottitis.

A second measure protects the people around a sick child. When someone develops invasive Hib disease, unvaccinated or incompletely vaccinated household contacts — especially young children — may be given a short course of a preventive antibiotic, usually rifampin, to clear any Hib they might be carrying before it can cause disease. This is called chemoprophylaxis, and it is directed by public-health guidance rather than used routinely.

Prevention is harder for the non-typeable strains, because there is currently no licensed vaccine for NTHi — it remains an active area of research. Sensible measures that reduce NTHi illness include general respiratory hygiene, not smoking (and avoiding secondhand smoke), which markedly lowers the risk of both childhood ear infections and adult COPD, and breastfeeding, which is associated with fewer ear infections in infancy. For adults with COPD, the broader package of not smoking, staying current on recommended respiratory vaccines, and treating flare-ups promptly all help limit the damage NTHi can do.

Research Papers

  1. Pittman M. Variation and type specificity in the bacterial species Hemophilus influenzae. Journal of Experimental Medicine. 1931;53(4):471–492. doi:10.1084/jem.53.4.471 — The foundational study that defined the six capsular types (a–f) and singled out type b, giving us the framework still used today.
  2. Adams WG, Deaver KA, Cochi SL, et al. Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era. JAMA. 1993;269(2):221–226. doi:10.1001/jama.1993.03500020055031 — An early, widely cited report documenting the dramatic collapse of childhood Hib disease in the United States after conjugate vaccine introduction.
  3. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clinical Microbiology Reviews. 2000;13(2):302–317. doi:10.1128/CMR.13.2.302 — A comprehensive global review of the Hib disease burden and the impact of vaccination.
  4. Morris SK, Moss WJ, Halsey N. Haemophilus influenzae type b conjugate vaccine use and effectiveness. The Lancet Infectious Diseases. 2008;8(7):435–443. doi:10.1016/S1473-3099(08)70152-X — A systematic look at how well Hib conjugate vaccines perform in real-world use across different settings.
  5. Sethi S, Murphy TF. Infection in the pathogenesis and course of chronic obstructive pulmonary disease. New England Journal of Medicine. 2008;359(22):2355–2365. doi:10.1056/NEJMra0800353 — A major review establishing non-typeable H. influenzae as the leading bacterial driver of COPD exacerbations.
  6. Murphy TF, Faden H, Bakaletz LO, et al. Nontypeable Haemophilus influenzae as a pathogen in children. Pediatric Infectious Disease Journal. 2009;28(1):43–48. doi:10.1097/INF.0b013e318184dba2 — Reviews the growing role of capsule-free NTHi in childhood ear infections and other disease.
  7. Watt JP, Wolfson LJ, O'Brien KL, et al. Burden of disease caused by Haemophilus influenzae type b in children younger than 5 years: global estimates. The Lancet. 2009;374(9693):903–911. doi:10.1016/S0140-6736(09)61203-4 — The global estimate of roughly 8 million serious Hib illnesses and about 370,000 child deaths in the year 2000, underscoring the stakes of vaccination.
  8. Agrawal A, Murphy TF. Haemophilus influenzae infections in the H. influenzae type b conjugate vaccine era. Journal of Clinical Microbiology. 2011;49(11):3728–3732. doi:10.1128/JCM.05476-11 — Describes how the epidemiology shifted toward non-typeable and non-b strains once Hib was suppressed by vaccination.
  9. King P. Haemophilus influenzae and the lung. Clinical and Translational Medicine. 2012;1(1):10. doi:10.1186/2001-1326-1-10 — Focuses on how NTHi colonizes and injures the airways in chronic lung disease.
  10. Van Eldere J, Slack MPE, Ladhani S, Cripps AW. Non-typeable Haemophilus influenzae, an under-recognised pathogen. The Lancet Infectious Diseases. 2014;14(12):1281–1292. doi:10.1016/S1473-3099(14)70734-0 — Argues that NTHi is a substantial and frequently overlooked cause of disease across all ages in the post-Hib-vaccine world.

Back to Table of Contents

Connections

Back to Table of Contents